DiaSorin has announced the launch of its sixth molecular diagnostic test on its Liaison IAM platform for the detection of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) on plasma and serum samples. The Herpes Simplex Virus (HSV), often contracted in early childhood, is contagious, usually not recognised by the patient and is latent after infection and can reactivate periodically. When, however, infections are symptomatic, they typically involve oral lesions that heal within two to three weeks or genital lesions. The new DiaSorin IAM HSV test, available on the market outside of the USA and Canada, enriches the existing molecular diagnostics offer of the group made of: BK Virus (IAM BKV), Varicella Zoster Virus (IAM VZV), Toxoplasmosis (IAM TOXO), Parvovirus (IAM PARVO) and Cytomegalovirus (IAM CMV).
The IAM HSV will be of primary importance for: infants and immunocompromised people; transplant and immunocompromised patients; and pregnant women. Paul Eros, global vice president Molecular, DiaSorin, commented: “HSV represents a serious danger for transplant patients and for the immunocompromised, as well as for babies when the mother contracted a primary infection during pregnancy. We are therefore proud to have introduced this test in our molecular diagnostics offer, confirming once again that we are a major player in the area of infectious diseases and being sure of having developed a test that can improve the health of people, sometimes even by saving the life”.
